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1. Introduction
Cationic lipid bilayers, particles, polysaccharides and a variety of hybrid nanostructures
provide adequate matrixes for supporting antigens such as peptides, proteins, DNA or
oligonucleotides on model surfaces (latex, silica, silicon wafers, self-assembled monolayers,
metals, polymers, insoluble drugs, biological cells and viruses).Particulate vaccines are
currently an area receiving a high level of attention [1-3]. Particles deliver both antigen and
adjuvant into the same population of antigen presenting cells limiting both the systemic
distribution of the adjuvant and its potential toxicity [1]. Biological particlesrepresented by
live or attenuated bacterial vacines, engineered biological vectors and virus-like particles are
often less safe than synthetic particulates for which quality control and validation in vaccine
development and production are more rapid [2]. While developing novel particulate vaccines,
particle size and charge do matter [2]. Virus-sized particles (20–200 nm) are usually taken up
by endocytosis via clathrin-coated vesicles, caveolae or their independent receptors [4], and
preferentially ingested by dendritic cells (DC). Larger sized particles such as bacteria (500–
5000 nm) are predominantly taken up by phagocytosis, and primarily ingested by macro‐
phages. All particles used in vaccine formulations are consequently internalized efficiently by
antigen presenting cells by one or a combination of the quoted mechanisms [5, 6]. Particles
with diameters smaller than 500 nm, in particular the nanometric ones with sizes in the 40–
100 nm range are more eficient to promote CD8 and CD4 type 1 T cell responses than those
with diameters above 500 nm, although the latter could induce good type 2 and antibody
responses [5]. Cationic microparticles are effectively taken up both by macrophages and
dendritic cells since electrostatic attraction promotes particle binding and subsequent inter‐
nalization. Cationized polymeric particles carrying antigen significantly enhanced both
antibody production and cytotoxic T cells at low antigen dose [7] and induced maturation of
dendritic cells [8, 9]. As a consequence particles for vaccines should be positive and available
over a range of sizes. Cationic particles of aluminium compounds, identified as having
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immunostimulatory properties more than 70 years ago, remain the only type of adjuvant
licensed world-wide [3]. Oil-in-water emulsions or virosomes were licensed in some countries
in compositions for influenza [10] or hepatitis B vaccines [11]. However, both of these adjuvants
are characterised by inducing humoral immune response and are thus effective in elevating
serum antibody titers whereas their ability to elicit cell-mediated immune response is limited
[12]. For vaccines against influenza, malaria and HIV, the induction of a humoral response is
insufficient and a substantial complementary cell-mediated immune response is necessary for
adequate protection. For vaccines against tuberculosis, a cellular response seems to be the sole
effector mechanism required for protection [13]. Among the cationic compounds used to
produce cationic nanostructures to present antigens for vaccines formulations, some cationic
compounds appear to be of special relevance.They are the cationic and synthetic lipid named
dioctadecyldimethylammonium bromide (DODAB), the cationic polysaccharide named
chitosan (CH) and its derivatives with pH-independent positive charge and the biocompatible
cationic polymeric nanostructures.This chapter presents and critically evaluates these three
types of cationic nanostructures.
2. Cationic nanostructures based on DODAB
DODAB is a cationic lipid which can be dispersed ultrasonically in aqueous solution using a
macrotip probe [14]. Thereby, bilayer vesicles are simultaneously obtained and disrupted
yielding nano-sized bilayer disks or cationic bilayer fragments (BF) stabilized by electrostatic
repulsion at low ionic strength [14,15].DODAB BF have previously been used as antimicrobial
agents [16] or in the production of lipid-covered particles such as bilayer-coated silica [17] or
latex [18]. These cationic, bilayer-covered latex or silica particles where the bilayer is solely
composed of DODAB were recently employed to present antigens to the immune system with
better results than alum as adjuvants for induction of cellular immune responses [19, 20]. The
open DODAB BF in aqueous dispersions are different from their mother vesicles presenting
the following features: (i) osmotic non-responsiveness of the dispersion indicative of absence
of inner vesicle compartment [21]; (ii) discoidal shape with disks exhibiting one bilayer
thickness as visualised by means of transmission electronic microscopy (TEM) after electronic
staining the nanostructures [22]; (iii) cryo-TEM micrographs performed without any staining
[23]; (iv) fluid and solid state coexistence and complex formation with oppositely charged
surfactant [24]; (v) solubilization of hydrophobic drugs at the borders of DODAB bilayer
fragments, which does not occur for DODAB closed bilayer vesicles [25]. These bilayer
fragments have more fluid environments at their edges that are absent in closed bilayer systems
such as vesicles or liposomes. Due to its cylindrical molecular shape, DODAB molecules self-
assemble in aqueous solutions as bilayers instead of micelles as shown in the seventies by
transmission electron microscopy [26]. Supramolecular assemblies of DODAB bilayer frag‐
ments by themselves or after interaction with supporting particles have been combined with
different model antigens in separate and tested as immunoadjuvants. The cationic nanoadju‐
vants with DODAB BF are either reduced to a single-component, nanosized system-DODAB
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BF-or are dispersions of cationic particles with controllable nature and size as obtained after
covering silica or polystyrene sulfate latex (PSS) with a cationic DODAB bilayer (Figure 1).
Figure 1. Cationic nanostructures and particles based on the cationic lipid DODAB useful to present antigens (repro‐
duced with permission from [27]).The DODAB bilayer fragments are usually obtained at low ionic strength by sonica‐
tion with a macrotip.Particles acting as supports for the cationic bilayer can be organic or inorganic. Reprinted from
Vaccine, 27/42, Nilton Lincopan,Noelí M. Espíndola,Adelaide J. Vaz,Maria Helena B. da Costa,Eliana Faquim-
Mauro,Ana M. Carmona-Ribeiro, Novel immunoadjuvants based on cationic lipid: Preparation, characterization and
activity in vivo, 5760-5771.Copyright 2009, with permission from Elsevier.
DODAB BF may interact with proteins both via the hydrophobic effect and the electrostatic
attraction at low ionic strength. This interaction has been properly characterized by means of
dynamic light scattering for sizing, zeta-potential analysis and evaluation of immunoadjuvant
activity in vivo. The model antigens employed with DODAB-based cationic nanostructures
were bovine serum albumin (BSA), purified 18 kDa/14 kDa antigens from Taenia crassiceps
cysticerci (18/14-Tcra) or a recombinant heat-shock protein from Mycobacterium leprae [27].
Antigen choices were due to different reasons. BSA adsorption at interfaces [28] and, specifi‐
cally, onto large DODAB vesicles [29] is well described and has been useful to prevent
nonspecific binding in immunoassays, biosensing and proteomics applications [28,30].The
purified 18 kDa/14 kDa antigens from Taenia crassiceps cisticerci are proteins specific for this
parasite found as circulating antigens and often employed in immunodiagnosis;they can be
obtained from in-vitro cultures of T. crassiceps cysticerci in hybridoma media from vesicles
budding from cysts contain the excretory/secretory (ES) antigens [31,32]. Human and pig
infections by T. solium and crassiceps, respectively, represent an important health problem, with
socio-economical repercussions affecting many countries in Latin America, Asia and Africa
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[31]. The 18 kDa-hsp protein is a heat-shock protein of M. leprae displaying pronounced
immunogenicity and considered able to induce proliferation of peripheral blood mononuclear
cells and T-cell lines from M. leprae vaccinated subjects [33] andavailable at large amounts for
studies on vaccine formulation; its overexpression and scaling-up in Saccharomyces cerevisae
have already been described and the recombinant protein can be produced in large scale
[34,35]. Nanostructured cationic adjuvant/antigen complexes based on DODAB were charac‐
terized over a range of adjuvant and antigen concentrations. Figure 2 shows the effect of
antigen and adjuvant concentration on physical properties of the dispersions. Stable cationic
nanostructures are available over a limited range of adjuvant and antigen concentrations
which clearly depend on antigen nature and are different for different antigens.
Figure 2. Effect of time and DODAB concentration on the zeta-average diameter of DODAB/BSA (A) or DODAB BF/
18/14-Tcra complexes (B). In (A), the kinetics were obtained upon adding DODAB BF at a final concentration of 0.005
((▷), 0.01 (△), 0.02 (◁), 0.05 (○), 0.5 (◇), 0.8 (□), and 1.0 mM DODAB (◁) to 0.5 mg/mL BSA. In (B), the kinetics were
obtained upon adding DODAB BF at a final concentration of 0.0005 (□), 0.001 (○), 0.005 (▷), 0.01(▽), 0.05(◇), and 0.1
mM DODAB (△) to 0.05 mg/mL 18/14-Tcra. The effect of [DODAB] on zeta-potential of complexes with 0.5 mg/mL
BSA (C) or 0.05 mg/mL 18/14-Tcra (D) were obtained after 1 h interaction at 25 °C in 1 mM NaCl.Reproduced with
permission from reference [27].Reprinted from Vaccine, 27/42, Nilton Lincopan,Noelí M. Espíndola,Adelaide J.
Vaz,Maria Helena B. da Costa,Eliana Faquim-Mauro,Ana M. Carmona-Ribeiro,Novel immunoadjuvants based on cati‐
onic lipid: Preparation, characterization and activity in vivo,5760-5771.Copyright 2009, with permission from Elsevier.
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The humoral and cellular immune responses induced by stable cationic adjuvant/antigen
complexes were evaluated in mice from determination of antigen-specific-IgG antibody in
serum by ELISA, delayed type hypersensitivity (DH) reactions from footpad swelling tests
and cytokines analysis. The results evidence the good colloid stability of the complexes,
complete absence of toxicity in mice (i.e. local or general reactions) and their potential utility
to induce Th 1 immune response at reduced doses of cationic and toxic DODAB lipid. Possibly
due to its chemical stability and low cost when compared to other natural or synthetic lipids,
DODAB use as an immunoadjuvant started more than forty years ago [36,37]. This was well
before the bilayer nature of DODAB self-assembly in water solution had been described [26].
DODAB as an effective immunoadjuvant has been intensively investigated aiming at subunit
vaccine design [38-41]. A major problem of liposomal formulations based on DODAB has been
the usually high concentration employed, namely 1-10 mM DODAB [38-41]. DODAB is a
cationic lipid and as such, cytotoxic [14-16] requiring dose minimization for administration in
vivo. Using the DODAB bilayer fragments to present antigens only 0.1 mM DODAB was
employed [27]. The large cellular imune response achieved might be related to the total surface
area available for antigen association, which is much larger in the BF dispersion than in closed,
large and sometimes multibilayered liposomes. Moreover, the hydrophobic interaction
possibly available from BF edges could be an additional and powerful driving force for antigen
adsorption and presentation. The second advantage of the bilayer fragments besides their large
surfaces area is their size. Depending on sonication power and time plus composition of the
dispersing medium, which determine colloid stability, DODAB BF/antigens complexes may
have their sizes reduced to and stabilized at a few tenths of nanometers acting similarly to
solid inert beads of nanometric size (40-50 nm). These beads turned out to be effective for
antigen delivery to antigen-presenting cells (APC), generating potent and combined humoral
and CD8+T cell immunity [3]. They are also expected to be optimal for dendritic cells uptake
since their size is inside the range of particle diameters (500 nm and below) for optimal
dendritic cells uptake of antigens and elicitation of an adequate cellular response [2,5,42]. In
reconstituted pig gastric mucus, sub-200 nm particulates from poly (D, L-lactic-co-glycolic)
acid and DODAB condensing DNA on particles surface exhibited improved transport rates,
stability in mucus, and ability to transfect cells [43]. Silica/DODAB, latex/DODAB and DODAB
BF (Figure 1) are available over the sub-200 nm range of sizes thus presenting potential also
for design of mucosal vaccines. The third advantage of the bilayer fragments is the absence of
depots at the injection site [27]. These depots have been reported for other DODAB formula‐
tions at concentrations much higher than 0.1 mM [37,41,44].
Consistently with electrostatic forces between negatively charged antigens and positively
charged DODAB BF, cationic bilayer fragments readily adsorb BSA, 18-14/Tcra and the hsp-18
kDa recombinant protein.Rapid and extensive adsorption of BSA, anti-BSA or ovalbumin onto
large DODAB liposomes was indeed reported previously [29,45,46].On the other hand,
bacteria, fungus and eukaryotic cells were also found to adsorb DODAB vesicles and bilayer
fragments with high affinity at low ionic strength [14-16], so that cationic DODAB liposomes
readily adsorb antigen, such as ovalbumin, and bind avidly to dendritic cells [41], thereby
enhancing antigen uptake. Delivery of antigen to cells by immediate contact with the cell
surface via electrostatic interaction followed by the induction of active uptake seems to be the
mechanism behind the ability of DODAB liposomes or bilayer fragments to act as immunoad‐
juvants. Sizes and zeta-potentials for assemblies of antigen and cationic lipid based adjuvants
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depend on cationic lipid and antigen concentrations. Adjuvant-antigen stability around sizes
that are close to the one of adjuvants themselves indicates that the proteins readily adsorb and
stabilize them. The adjuvants also stabilized the proteins acting as important dispersing
nanocarriers able to induce remarkable degree of protein disaggregation by attaching the
proteins either electrostatically or hydrophobically to their structure. At [DODAB] ≤ 0.1 mM
and 0.001-0.05 mg/mL of antigen concentration, DODAB based adjuvant /antigen assemblies
are cationic, well-dispersed, colloidally stable and immunogenic combining the advantages of
low DODAB dose, low cost, controllable sizes for optimal dendritic cells uptake, high chemical
stability, ability to incorporate multiple antigens and minimization of toxicity. Their perform‐
ance is remarkably superior to the one of alum as adjuvant regarding Th1 mediated responses.
In contrast to alum or cationic liposomes at 1-10 mM of cationic lipid, local or systemic adverse
effects in mice were completely absent at 0.1-0.01mM DODAB.
An important component of the early innate immune response to viruses and bacteria is the
secretion of cytokines, which mediate many of the effector functions of innate immunity. IL-10
is an inhibitor of activated macrophages and dendritic cells and is an example of negative
feedback regulation because it is produced by macrophages to inhibit their function. This
cytokine also inhibits the production of IL-12 and expression of class II major histocompati‐
bility (MHC) molecules. IL-12 is also secreted by macrophages and dendritic cells inducing T
cells differentiation into Th1 and natural killer (NK) cells with increased IFN-gamma synthesis
and cytotoxic activity. IL-12 and IFN-gamma are the most important cytokines in innate
responses to intracellular bacteria such as Mycobacterium leprae or tuberculosis [13]. Figure 3
shows the high levels of IL-12 and IFN-gamma induced by the novel cationic adjuvants while
presenting the hsp-18 kDa of M. leprae to lymphonode cells suggesting a possible application
of the novel adjuvants for the design of subunit vaccines against intracelular bacteria. As in
DH, adaptive immunity against intracellular bacteria is principally cell mediated and consists
of activation of macrophages by CD4+T cells as well as killing of infected cells by CD8+cyto‐
toxic T lymphocytes (CTL).
On basis of IL-12 enhancement of IFN-gamma production and development of Th1 cells, this
interleukin itself has been used as a vaccine adjuvant for many infections that are combated
by cell-mediated immunity, e.g. leishmaniasis [47]. Subunit vaccines against protozoa that
survive within macrophages require as principal defense mechanism cell-mediated immunity,
particularly directed to macrophage activation by Th1 cell-derived cytokines. Leishmaniasis
mucocutaneous and disseminated is caused by Leishmania donovani and CD4+Th1 cells are
required to activate macrophages to kill phagocytosed parasites. Resistance to the infection is
associated with activation of Leishmania-specific Th1 CD4+T cells which produce IFN-gamma
and thereby activate macrophages to destroy intracellular parasites. Conversely, activation of
Th2 cells by the protozoan results in increased parasite survival and exarcerbation of lesions
because of the macrophage-suppressive actions of Th2 cytokines [47]. Other significant
example is the protective role played by CD8+T cells in immunity to the hepatic stages of
malaria. These effects may be mediated by direct killing of sporozoite-infected hepatocytes or
indirectly by the secretion of IFN-gamma and activation of hepatocytes to produce nitric oxide
and other agents that kill parasites. IL-12 induces resistance to sporozoite challenge in rodents
and nonhuman primates, presumably by stimulating IFN-gamma production [48].
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In viral infections, Il-12 enhances the cytotoxic activity of natural killer cells so that NK cell-
mediated killing of virus-infected cells eliminates the reservoir of infection. In this respect,
vaccination against the dengue virus is urgently needed in tropical or neotropical regions of
the planet and some recombinant DNA vaccines expressing membrane and envelope of viral
proteins have been proposed [49]. Possibly the cationic adjuvants available from our group
would properly enhance the required Th-1 response for a more effective vaccination against
dengue.
Another possible application for the novel adjuvants might be in immunotherapy for tumors.
This approach is based in augmentation of host immunity to tumors with tumor vaccines.
Immune responses that are able of killing tumor cells consist of CTLs, NK cells, and activated
macrophages and these may be actively enhanced by vaccination with tumor cells or antigens,
administration of tumors modified to express high levels of cytokines that stimulate T cell
proliferation and differentiation, and systemic administration of cytokines [49]. The induction
of T cell responses in tumors depends on processing and presentation of tumor antigens to T
cells by professional antigen-presenting cells (APCs) which might internalize the tumor
antigen adsorbed onto the novel cationic adjuvants. These APCs may stimulate CD8+T cells
and CD4+helper T lymphocytes to differentiate for recognition and killing of tumor cells.
Naïve CD4+T cells may differentiate into distinct subsets, such as Th1 and Th2 cells in response
to different antigens. For example, the enhancement in production of IL-10 and Il-13 by
lymphonode cells elicited by the antigens of Taenia crassiceps presented by the DODAB BF
adjuvant can be appreciated in Figure 3 [27]. These cytokines are typically associated with
responses to allergens and parasites such as helminths and mediate differentiation of CD4+-T
cells into Th2 cells [50]. Consistently, low levels of these cytokines were elicited by the M.
leprae antigen presented by the novel adjuvants (Figure 3). Responses were indeed different
for the helminthes and the bacteria antigens and very antigen-specific as they should be [27].
The size, charge and hydrophobic features of DODAB BF led to novel applications in solubi‐
lization of hydrophobic drugs [25,51,52], production of biomimetic particles from bilayer
coverage of silica [17] or polystyrene particles [53] and design of vaccines [27].Recently, BF
was also combined with oligonucleotides [54]. Since synthetic oligonucleotides can inhibit the
replication of the Rous sarcoma virus [55], antisense oligonucleotides have been considered a
great promise as therapeutic agents and several oligonucleotide-based formulations have
reached the clinical trial phase [56,57]. Antisense oligonucleotides have also been extensively
used in research on gene expression and function [58-60], vaccine formulation [61], allergy [62]
and cancer therapeutics [63].Major obstacles as their degradation by nucleases and poor
delivery to the target cells [60,64] suggest the essential role of suitable carriers able to protect
oligonucleotides in the biological milieu [60,63–65].There are peculiar features for the interac‐
tion between BF and oligonucleotides in comparison to other electrolytes.Effects of salt, dAMP
or poly (dA) concentration on BF size and zeta-potential are shown on Figure 4 taken from
reference [54]. From 0 to 0.25 mM salt, Dz and zeta-potentials decreased with salt concentration
possibly due to massive phosphate anion binding. From 0.25 to 2.5 mM of divalent salt, Dz
increased but zeta-potential remained approximately constant and low (Fig. 4A and D).Dz and
zeta-potential decreased with dAMP concentration (0– 2.5 mM) (Fig. 4B and E). At 0.05 mM
poly (dA) and 0.5 mM DODAB, extensive BF aggregation and/or fusion took place as depicted
from large Dz (N 500 nm) (Fig. 4C) and zero of zeta-potential (Fig. 4F). The screening of DODAB
Cationic Nanostructures for Vaccines
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Figure 3. Quantitative analysis of cytokines secreted by lymph node cells from DODAB/18/14-Tcra and
Al(OH)3/18/14-Tcra immunized mice (on the left column, A-D) or from 18kDa-hsp, DODAB/18kDa-hsp, PSS/DODAB/
18kDa-hsp, SiO2/DODAB/18 kDa-hsp and Al(OH)3/18kDa-hsp immunized mice (on the right column, E-F). Cells from
lymph nodes of BALB/c mice previously immunized with 10 μg of 18/14-Tcra administered alone, in DODAB BF or in
Al(OH)3 were in vitro stimulated with medium, 160 μg/ml of 18/14-Tcra or 2.5 µg/mL of ConA for 48 hours and the
supernatants collected for cytokine analysis by sandwich kit enzyme-linked immunosorbent assay (ELISA). The results
were expressed as mean of the cytokine concentration of two distinct assays ± standard deviation. Limits of detection
are shown as horizontal dashed lines. Similarly, cells from lymph nodes of BALB-c mice previously immunized with 15
μg of 18 kDa-hsp from M. leprae administered alone or in DODAB BF, PSS/DODAB, silica/DODAB or Al (OH)3 were in
vitro stimulated with medium, 250 μg/ml of 18 kDa-hsp or 2.5 µg/mL of ConA for 48 hours before following cytokines
analysis as above (reproduced with permission from reference [27]). Reprinted from Vaccine, 27/42, Nilton Lincopan,
Noelí M. Espíndola, Adelaide J. Vaz,Maria Helena B. da Costa, Eliana Faquim-Mauro, Ana M. Carmona-Ribeiro, Novel
immunoadjuvants based on cationic lipid: Preparation, characterization and activity in vivo, 5760-5771.Copyright
2009, with permission from Elsevier.
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charges by Na2HPO4, followed by a decrease in electrostatic repulsion between fragments,
could be responsible for DODAB BFs aggregation and/or fusion. DLS data also showed that
diameters increase upon addition of Na2HPO4 concentrations above 0.5mM (Figure 4A), and
this diameter increase up to 400 nm is related to a decrease in the zeta-potential of the fragments
(Figure 4D). The charge screening of DODAB charged heads by Na2HPO4 explains the decrease
in zeta-potential (Figure 4D) as well as the tighter bilayer packing represented by higher mean
phase transition temperature for the bilayer [54]. Addition of dAMP leads to a decrease in
diameter and zeta-potential of the assemblies (Figures 4B and E). It was shown that DODAB
bilayer fragments are able to order dAMP molecules on their surface, causing the dAMP bases
to stack [68]. In this case, bulky moieties of dAMP would be exposed at the fragments surface
representing a steric hindrance to fragments aggregation and/or fusion which would also
contribute to colloid stabilization in dispersion. For polynucleotides such as poly(dA), charge
neutralization leads to flocculation whereas charge overcompensation upon increasing
poly(dA) concentration leads to colloidal restabilization due to electrostatic repulsion (Figures
4C and F) [54]. This behavior has been often described for polyelectrolytes interacting with
particles of opposite charge [67,68]. Beyond the neutralization point, the system regains
stability due to charge overcompensation. This phenomenon was observed only for the
electrolyte poly (dA) and not for the electrolytes Na2HPO4 and dAMP, which are unable to
completely neutralize the bilayer [54], as shown in Figure 4. Colloid instability induced by
oligonucleotide or salt could be associated with bilayer fusion [54]. In contrast, mononucleo‐
tide neither reduced colloid stability over the low range of concentrations tested nor caused
BF fusion [54].
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Particles are finding a large variety of biomedical and pharmaceutical applications since their
size scale can be similar to that of biomacromolecules (e.g., proteins, DNA) and structures (e.g.,
bacteria and viruses). Their utility for imaging, gene and drug delivery, and vaccine design is
undeniable [69,70].Particulate systems are naturally targeted to antigen presenting cells (APC)
so that particles deliver antigens to APC more efficiently than soluble antigen [71,72].Positively
charged particles with diameters of 500 nm and below were shown to be optimal for dendritic
cells uptake [42].DODAB bilayers electrostatically combine with a vast variety of negatively
charged biomolecules or biological structures [14]. Silica [17], latex [21,73,74] or hydrophobic
drug particles [51,75] have been coated with DODAB with optimal bilayer deposition on
particles achieved by coalescence of bilayer fragments at an adequate ionic strength [17,76].
Figure 5 shows how DODAB can cover oppositely charged polystyrene nanoparticles modi‐
fying their charge as shown in reference [19]. These cationic nanoparticles contrast with alum
regarding their small size and very low polydispersity as shown in Table 1 taken from reference
[19]. The optimal bilayer coverage of polystyrene sulfate (PSS) nanoparticles with a DODAB
bilayer produces homodisperse particles that successfully present a mixture of purified 18/14
Taenia crassiceps proteins (18/14-Tcra) to the immunological system [19].
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ceutics, 340 / 1–2, N. Lincopan, N.M. Espíndola, A.J. Vaz, A.M. Carmona-Ribeiro, Cationic supported lipid bilayers for
antigen presentation, 216-222.Copyright 2007, with permission from Elsevier.
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Dispersion [DODAB](mM)
[Ag]
(μg/mL)
Mean diameter
(nm)
Zeta-Potential
(mV) Polydispersity
PSS - - 301 ± 2 -60 ± 1 0.064 ± 0.020
DODAB 2.00 - 81 ± 1 45 ± 2 0.230 ± 0.006
PSS/DODAB 0.01 - 309 ± 2 48 ± 2 0.040 ± 0.010
18/14-Tcra - 25 310 ± 5 -52 ± 1 0.214 ± 0.030
DODAB/18/14-Tcra 0.01 25 295 ± 3 6 ± 6 0.167 ± 0.023
PSS/DODAB/18/14-Tcra 0.01 25 328 ± 3 11 ± 8 0.060 ± 0.020
Al(OH)3 - - 883 ± 29 28 ± 3 0.381 ± 0.013
Al(OH)3/18/14-Tcra - 25 9574 ± 2361 -23 ± 1 0.525 ± 0.030
Table 1. Physical properties of particles, DODAB dispersion, DODAB-covered particles, proteins and proteins/DODAB-
covered particles at 1 mM NaCl.Particles concentration is 5 x 109 particles /mL; PSS particle diameter from transmission
electron microscopy is 301±2 nm.The Al(OH)3 and PSS were tested at final concentration of 0.05 and 0.075 mg/mL,
respectively,from reference [19]. Reprinted from International Journal of Pharmaceutics, 340 / 1–2, N. Lincopan, N.M.
Espíndola, A.J. Vaz, A.M. Carmona-Ribeiro, Cationic supported lipid bilayers for antigen presentation, 216-222.
Copyright 2007, with permission from Elsevier.
Several cationic agents have been employed for DNA compaction such as cationic peptides
and proteins [77], cationic lipids [78], cationic polyelectrolytes, cationic surfactants, or iron (III)
[79].DNA compaction has also been used to model chromatin structure and its influence on
gene expression. The self-assembled complex of basic histone proteins wrapped by approxi‐
mately two turns of DNA is a nucleosome, which is the building block in the chromatin
structure where DNA of lengths on the order of meters suffers compaction into an∼10 μm
diameter cell nucleous. Phage DNA, for example, is remarkable for its density of packing. In
solution the 40 kbp T7 genome with its contour length of 13.6 μm might span a space several
micrometers across and in an infected bacterium, ∼1 μm across. Thus, confinement to a 55 nm
capsid represents a compaction marked by a density increase by a factor of ∼104 [80]. System‐
atic studies on the physical chemistry of the association between cationic nanoparticles and
DNA yield rather complex phase diagrams as a function of particle size and concentration
[81,82].The way in which positively charged nanoparticles tie up DNA is not obvious, and
mechanisms change dramatically with particle size [83]. Only the smallest (10 nm) particles
allowed transcription to occur at intermediate loading densities. Larger particles shut tran‐
scription down rather abruptly [81]. Cationic nanoparticles have found many uses such as
efficient cell transfection agents in vitro [84-86] and complexation with long-chained DNA as
a simple model of chromatin for transcription studies [81, 87].The compaction of long duplex
DNA by cationic nanoparticles (NP) used as a primary model of histone core particles has been
systematically studied regarding the effect of salt concentration, particle size, and particle
charge by means of single-molecule observations from fluorescence and transmission electron
microscopy [87]. DNA compaction proceeds through the formation of beads-on-a-string
structures of various morphologies with DNA adsorbed amount per particle depending
weakly on NP concentration but increasing with particle size and being optimal at an inter‐
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mediate salt concentration [87]. Three different complexation mechanisms were proposed: free
DNA adsorption onto NP surface, DNA wrapping around NP, and NP collection on DNA
chain [87]. On the other hand, particle size has been recognized as an important parameter that
determines the mechanism of particle entry into cells. Particles with a diameter of 200 nm or
less enter cells almost exclusively via the clathrin-coated pathway whereas particles with a
larger diameter penetrate cells via caveolae-mediated endocytosis [88,89].Cationic biomimetic
particles produced from adsorption of dioctadecyldimethylammonium bromide (DODAB)
bilayers onto polystyrene sulfate (PSS) microspheres have been described by our group since
1992 [18,73,76,90].These cationic bilayer-covered particles exhibit a narrow size distribution
and can be produced at any desired size ranging from 70-500 nm of mean hydrodynamic
diameter [90]. Polystyrene sulfate (PSS) particles with different sizes were covered by a
dioctadecyldimethylammonium bromide (DODAB) bilayer yielding the so-called cationic
biomimetic particles (PSS/DODAB). These cationic particles are highly organized, present a
narrow size distribution and were obtained over a range of particle sizes [53,90].Thereafter,
upon adding λ, T5 or T2-DNA to PSS/DODAB particles, supramolecular assemblies PSS/
DODAB/DNA were obtained and characterized over a range of DNA concentrations and
particle sizes (80-700 nm). Over the low DNA concentration range, PSS/DODAB/DNA
assemblies were cationic, colloidally stable with moderate polydispersity and high cytotoxicity
against E. coli. From the DNA concentration corresponding to charge neutralization, neutral
or anionic supramolecular assemblies PSS/DODAB/DNA exhibited low colloid stability, high
polydispersity and moderate cytotoxicity [53]. Some nucleosome mimetic assemblies were
observed by atomic force microscopy (AFM) at charge neutralization (zeta-potential equal to
zero) [55].Figure 6 shows how cationic nanoparticles can induce DNA compaction [53].
Figure 6. DNA compaction by biomimetic cationic particles of polystyrene microspheres covered by a DODAB cationic
bilayer from reference [53].Adapted with permission from Rosa H, Petri DF, Carmona-Ribeiro AM.Interactions be‐
tween bacteriophage DNA and cationic biomimetic particles. J Phys Chem B. 2008; 112(51):16422-30.Copyright
(2008) American Chemical Society.
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DNA sequences containing unmethylated CpG dinucleotide are recognized as danger signals
by the immune system since they are typical of bacteria and viruses but rare in vertebrates [91,
92]. Natural or synthetic sequences containing unmethylated CpG motifs activate cells that
express Toll-like receptor 9 to induce an innate immune response characterized by the
production of Th1 and proinflammatory cytokines [92]. Hence, CpG has been extensively used
in the induction of cellular immune responses against cancer [63, 93], intracellular infections
by pathogens [94, 95] and allergies [62,96]. Both CpG [92] and DODAB BF [27] were reported
to improve Th1 responses against antigens when used separately. Recently, DODAB BF and
CpG were combined in a single assembly aiming at the comparison between the small, stable
and cationic DODAB BF carrying ovalbumin (OVA) and the small, stable and anionic DODAB
BF/OVA/CpG assemblies of very similar sizes but opposite charges [97]. Both adjuvants
produced similar enhanced Th1 immune responses despite their opposite charges emphasiz‐
ing the novel concept that particle charge does not matter. In comparison with the traditional
alum, the size minimization for the cationic assemblies elicited different responses: alum drove
the Th2 whereas DODAB BF/OVA/CpG and DODAB BF/OVA drove the Th1 response. The
effects of DODAB BF or DODAB BF/CpG adjuvants with opposite charges but very similar
sizes showed that the charge is not important but the size is [97]. Table 2 shows the physical
properties of the assemblies. A comparison between mean hydrodynamic diameter (Dz), zeta-
potentials and polydispersities for DODAB BF/OVA/CpG and Al(OH)3/OVA/CpG as repro‐
duced from reference [97]. At 20 μM CpG and 0.1 mg/mL Al(OH)3, the dispersion was
characterized by a low colloidal stability (large Dz, low zeta-potential (ζ) and high polydis‐
persity). OVA stabilized both Al(OH)3 or Al(OH)3/CpG to a certain extent (Table 2). However,
sizes were still larger than those determined for assemblies based on DODAB BF (Table 2). In
particular, polydispersity for DODAB BF/OVA/CpG was notably low (0.150) and well below
the one obtained for DODAB BF only (0.251), suggesting that OVA/CpG induced stabilization
of the DODAB BF dispersion (Table 2).
Dispersion Dz ± δ (nm) ζ ± δ (mV) Polydispersity ± δ
DODAB BF 67 ± 0 47 ± 1 0.251 ± 0.006
DODAB BF/ OVA 274 ± 2 21 ± 0 0.291 ± 0.008
DODAB BF/ OVA/ CpG 245 ± 1 -26 ± 1 0.150 ± 0.020
Al(OH)3 3147 ± 197 16 ± 2 0.415 ± 0.018
Al(OH)3/ OVA 916 ± 17 -29 ± 1 0.231 ± 0.020
Al(OH)3/ CpG 3584 ± 74 9 ± 1 0.407 ± 0.026
Al(OH)3/ OVA/ CpG 570 ± 19 -35 ± 2 0.210 ± 0.020
Table 2. Physical properties of alum or DODAB BF dispersions combined with ovalbumin (OVA) and/or CpG
oligonucleotide. Concentrations are 0.1mg/mL OVA, 0.1mM DODAB BF, 0.1mg/mL Al(OH)3 and 20μM CpG. Reprinted
from reference [97]. Reprinted from Journal of Controlled Release, 160/2, Julio H.K. Rozenfeld, Sandriana R. Silva,
Priscila A. Ranéia, Eliana Faquim-Mauro, Ana M. Carmona-Ribeiro, Stable assemblies of cationic bilayer fragments and
CpG oligonucleotide with enhanced immunoadjuvant activity in vivo, 367-373.Copyright 2012, with permission from
Elsevier.
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At 0.1 mg/mL OVA, the dependence of DODAB BF/OVA size and zeta-potential on time and
[DODAB] established 0.1 mM DODAB as suitable for obtaining stable and cationic DODAB
BF/ OVA assemblies [97]. At 0.1 mM DODAB, 0.1 mg/mL OVA and 0.006 mM CpG, the zeta-
potential is zero showing charge neutralization [97]. At [CpG]> 0.006 mM, good colloidal
stability for the anionic assemblies due to charge overcompensation was observed whereas at
0.020 mM CpG, these DODAB BF/OVA/CpG assemblies turned out to be highly effective in
vivo generating responses similar to those elicited by the stable and cationic DODAB BF/OVA.
The anti-OVA delayed-type hypersensitivity (DTH) reaction and the secretion of IFN-gamma
and IL-12 resulted 6, 42 and 9 times larger for the DODAB BF/OVA/CpG-immunized mice
than the same responses by OVA-immunized mice, respectively [97].Figure 7 A and B illustrate
the colloidal stability of the assemblies over a range of DODAB concentrations.
The delayed-type hypersensitivity reaction (DTH) is an important in vivo response mediated
by cells that can be quantified from the footpad sweelling test [44]. Mice immunized with OVA
alone or with DODAB BF/CpG or with OVA / Al(OH)3 exhibited a footpad swelling equal to
the one observed for naive mice [97]. The largest increase in footpad swelling was observed
for DODAB BF/OVA/CpG mice immunization, which was about 6 times larger than the one
observed for naive mice and 1.3 times larger than the one observed for DODAB BF/OVA [97].
Figure 7 C shows the improved DTH response in mice induced by the assemblies as adapted
from reference [97].
Since OVA isoelectric point is 4.5 [98], this protein is negatively charged at 6.3, the pH of water.
Thus, OVA adsorption onto DODAB BF is initially electrostatically driven.The OVA titration
with DODAB BF determined ranges of DODAB concentration for occurrence of stable DODAB
BF/OVA assemblies as illustrated in Figure 7 A and B. Similar results had been previously
described also for DODAB BF/ bovin serum albumin or DODAB BF/ purified antigens from
Taenia crassiceps [27].When the net charge of the assemblies is zero (at charge neutralization),
maximal aggregation was observed for the assemblies. Further increasing DODAB concen‐
tration, stabilized them to a certain extent (Figure 7 B). However, sizes and polydispersities
were still higher than those of DODAB BF in absence of OVA. Optimal colloidal stability was
only achieved upon CpG addition to the system yielding high and negative zeta-potentials
plus remarkably small polydispersity [98]. Oligonucleotides with less than 20 nucleotide
residues usually behave as rigid charged rods in solution [99]. CpG would also adsorb as rigid
charged rods on vacant positive sites of DODAB BF/ OVA assemblies inducing charge
overcompensation and recovery of colloidal stability as previously described for a model
oligonucleotide above charge neutralization [56].
Figure 7 also illustrates the improvement in the cellular OVA-specific response from the
analysis of cytokines secreted by lymph node cells of mice as adapted from reference [97]. IFN-
γ and IL-12 production is associated to the Th1 response whereas IL-10 and IL-13 production
reflects the Th2 response. Levels of IFN-γ and IL-12 secretion observed in cell cultures of mice
immunized with OVA or Al(OH)3/ OVA were low and close to the detection limit for these
cytokine assays (Figure 7). For mice immunized with OVA/CpG or DODAB BF/OVA assem‐
blies, the secretion of IFN-γ and IL-12 substantially increased in comparison to secretion from
cultured cells of OVA-immunized mice [97]. For the DODAB BF/OVA/CpG immunized mice,
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the secretion of IFN-γ and IL-12 increased by 33 and 49 %, respectively when compared to
DODAB BF/OVA-immunized mice group and 52% and 35% when compared to OVA/CpG-
group. In contrast, the highest secretion of IL-10 and IL-13 was observed in cultures of cells
from mice that were immunized with Al(OH)3 /OVA whereas all other assemblies resulted in
poor production of these cytokines [97]. Immune responses were similar for anionic DODAB
BF/OVA/CpG and cationic DODAB BF/OVA of similar sizes showing that the charge is not
important but the size is. The adsorption of antigen on the surface of DODAB large vesicles
was shown to stimulate active antigen capture and presentation by dendritic cells (DCs) [41].
Administration of antigen adsorbed on DODAB large vesicles (LV) resulted in formation of
an antigen depot at the site of injection which hampered the rapid clearance of antigen that
takes place in absence of a carrier [100]. In contrast to DODAB LV, the small DODAB BF/
antigen assemblies did not result in any observable depot effect [27, 97]. Furthermore, since
the depot was absent for DODAB BF/CpG/OVA the immunostimulatory effect must have
occurred via direct effect of the assemblies on the lymphonode antigen presenting cells [97].
Only nanoparticles can specifically target lymph node-resident cells [101]. CpG combined with
DODAB BF yielded improved cellular Th1 response [97] possibly due to the appropriate
targeting of DODAB BF/CpG/antigen to DCs in charge of expressing endosomal toll like
receptor 9 (TLR9) in the lymph nodes [102]. The enhanced Th1 response by anionic DODAB
BF/OVA/CpG relative to OVA alone was evidenced by the 6 times increase in DTH reaction,
the 42 times increase in IFN-γ secretion by lymph node cells in culture and the 9 times increase
in IL-12 secretion also by lymph node cells in culture (Figure 7) [97].
Other delivery systems based on anionic [103] or cationic lipid bilayer [41,44,100,104,105] have
also been successful for improving Th1 response against important antigens such as those of
influenza [103], hepatitis A and B [103,104], and fungal infections [105]. In general, cationic
lipids are known for the production of a large inflammatory response [41, 44].However, for
small cationic bilayer fragments as immunoadjuvants, this adverse reaction is absent [27, 97].
The small and anionic DODAB BF/OVA/CpG assemblies [97] also did not elicit adverse
reactions similarly to other anionic assemblies [103]. There was no depot effect for these small
assemblies [97] and their net negative charge ensured the absence of the adverse reactions
observed previously for the large cationic liposomes and vesicles [100]. Recently, based on
cross reactivity with Neisseria lactamica outer membrane vesicles (OMV) antigens, DODAB BF
were combined with OMV to develop a vaccine against Neisseria meningitidis in young children
[106]. Complexes of 25 μg of OMV in 0.1 mM of DODAB BF were colloidally stable, exhibiting
optimal physical properties for efficient antigen presentation [106].
3. Cationic nanostructures based on chitosan and other biocompatible
polymers
Chitin is a long-chain polymer of N-acetylglucosamine, a derivative of glucose which can be
deacetylated to yield chitosan as shown in Figure 8.
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Since they are biocompatible, biodegradable by deacetylases, mucoadhesive, and nontoxic,
with antimicrobial, antiviral, and adjuvant properties, chitin, chitosan and their derivatives
have been widely applied in medicine, pharmacy and vaccine design [107, 108]. Chitosan is
soluble in diluted acids but is insoluble in water due to deprotonation of its amino moiety
[109]. The poor solubility of chitosan at the pH of water represents a serious limitation for its
applications as an immunoadjuvant in the clinics [107]. Several chitosan derivatives have been
obtained to circumvent this limitation.For example, by attaching galactose moieties to the
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Figure 7. Nanostructures of cationic bilayer fragments and CpG oligonucleotide with enhanced immunoadjuvant ac‐
tivity in vivo. In (A), the effect of time and DODAB concentration on zeta-average diameter of DODAB BF/OVA assem‐
blies is seen from the kinetics obtained after adding DODAB BF at a final concentration of 0.005 (∎); 0.01 (○); 0.02 (▲);
0.05 (▽); 0.1 (◆); 0.2 (□); 0.5 (●) and 1mM DODAB (△) to 0.1mg/mL OVA. In (B), kinetical data are detailed for the
larger DODAB BF concentrations.Assemblies were prepared in 1mM NaCl.In (C), delayed-type hypersensitivity re‐
sponse for BALB/c mice immunized with OVA in different adjuvant formulations determined from the footpad swel‐
ling (nm) ± standard error of the mean. Final concentrations are 0.1mM DODAB BF, 20μM CpG and 0.1mg/mL Al(OH)3
and 0.1mg/mL OVA. p< 0.05 compared to naive (○), p< 0.05 compared to OVA/Al(OH)3 (#) and p< 0.05 compared to
OVA/DODAB/CpG (△) from reference [97].Adapted from Journal of Controlled Release, 160/2, Julio H.K. Rozenfeld,
Sandriana R. Silva, Priscila A. Ranéia, Eliana Faquim-Mauro, Ana M. Carmona-Ribeiro, Stable assemblies of cationic bi‐
layer fragments and CpG oligonucleotide with enhanced immunoadjuvant activity in vivo, 367-373.Copyright 2012,
with permission from Elsevier.
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chitosan molecules, a new water-soluble compound, glycated chitosan (GC), was synthesized
[109,110]. GC is a non-toxic biodegradable product used in laser immunotherapy (LIT) which
combines local laser irradiation and local administration of GC at primary or metastatic cancers
where the tumoral antigens of the irradiated tumor cells combined with GC elicit a potent
immune response against the cancer [111,112]. After the first step involving tumor irradiation
with a laser beam that causes swelling and disruption of tumor cells by thermal effect, the local
injection of GC as immunoadjuvant would lead to the capture of the tumoral antigens by
dendritic cells and migration to the lymph nodes where the antigens would be presented to T
cells, thus activating cytotoxic T-lymphocytes [113-115]. LIT using GC induced regression of
primary and secondary tumours in rats and caused resistance to repeated challenges with
tumours of the same type [116]. Furthermore, rats developed immunity could be adoptively
transferred [116].
Chitosan nanoparticles have been obtained by ionotropic gelation, complex coacervation,
emulsion and microemulsion techniques, and self-assembly of hydrophobically modified
chitosan [117]. Ionotropic gelation consists of the ionic crosslinking of chitosan with multiva‐
lent counter-ions such as sodium tripolyphosphate (TPP) by adding a dilute chitosan acid
solution to a solution of TPP or vice versa, with stirring [118]. Chitosan particles of nanometric
size were obtained for chitosan concentrations up to 2.8 g L−1 and TPP concentrations from 0.21
to 0.43 g L−1. The size and surface charge of particles can be modified by varying the ratio of
chitosan and stabilizer. The main problematic aspects of the technique are the poor colloidal
stability of the dispersion which may require the addition of stabilizers, and the need of using
very dilute solutions which may be inconvenient when large amounts of nanoparticles are
required [117]. Complex coacervation is achieved by mixing two oppositely charged polye‐
lectrolytes. The polyelectrolyte or coacervate complex is structured as nanoparticles. Chitosan–
poly (acrylic acid) (PAA) nanoparticles carrying a positive charge with sizes from 50 to 400
nm were obtained by the dropwise addition of dilute chitosan solutions [119]. Carboxyme‐
thylcellulose and alginate have also been complexed with chitosan to prepare nanoparticles.
Chitosan–carboxymethylcellulose nanoparticles were subsequently coated with plasmid DNA
(pDNA) [120]. Chitosan–alginate nanoparticles were loaded with insulin [121]. Nanoparticles
have also been obtained in which the polyanion is the active principle itself as for example
heparin or DNA or even siRNA. Chitosan–heparin nanoparticles crosslinked with TPP were
described [122]. Figure 9 shows on the left a scanning electron micrograph of chitosan– heparin
nanoparticles adapted from reference [117] and, on the right, an atomic force micrograph of
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Figure 8. Chitin yielding chitosan by deacetylation.
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chitosan-carboxymethylcellulose nanoparticles [123] prepared by complex coacervation
without using without using any organic solvent or crosslinker. These coacervates have the
interesting property of combining with cisplatin [123] but can also be combined with peptides,
proteins and DNA and therefore are potentially useful for vaccine design.
 
 
 
Ş
Figure 9. Nanoparticles obtained by complex coacervation of oppositely charged polyelectrolytes: chitosan-heparin
on the left [117] and chitosan-carboxymethylcellulose on the right [123].On the left, adapted with permission from
Peniche H, Peniche C. Polym Int. Chitosan nanoparticles: a contribution to nanomedicine.2011; 60:883–889. DOI:
10.1002/pi.3056, http://onlinelibrary.wiley.com/doi/10.1002/pi.3056/abstract. Copyright 2011, John Wiley and
Sons.On the right, adapted with permission from Vieira DB, Kim V, Petri DFS, Menck CFM, Carmona-Ribeiro AM. Supra‐
molecular assemblies of cisplatin and polyelectrolytes: preparation, characterization and activity against cancer cells.
In: Laudon M, Romanowicz B. (eds.) Nanotech Conference & Expo 2012: An Interdisciplinary Integrative Forum on
Nanotechnology, Microtechnology, Biotechnology and Cleantechnology, Santa Clara, CA, United States, June 18-21,
2012 (2012), 3, 182-185. Publisher: (CRC Press, Boca Raton, FLA) ISBN 978-1-4665-6287-5.
Other interesting chitosan derivatives have been synthesized and used for the preparation of
nanoparticles such as N-trimethylchitosan (TMC) and mono-N-carboxymethyl chitosan
(MCC) [124]. In general, mucosal applications of antigens result in poor immune responses.
Therefore, mucoadhesive adjuvants are required to enhance the immune response by improv‐
ing both antigen protection and its cellular uptake. Nanoparticles of TMC or MCC were
prepared using the ionic gelation method and loaded with tetanus toxoid (TT) exhibiting high
loading efficacy (>90% m/m), sizes within the range of 40-400nm and negative or positive
surface charge for MCC and TMC, respectively [124]. The structural integrity of the TT in the
formulations was confirmed by SDS-PAGE electrophoresis and the intranasal application in
mice elicited high serum IgG titres [124].Figure 10 illustrates the excellent uptake by macro‐
phages of these nanoparticles labeled with a green fluorescent marker as adapted from [124].
Due to the positive charge of chitosan and TMC, and the negative charge of TT, the antigen
loading is driven by the electrostatic attraction. There is also a superior association and
internalization of chitosan or chitosan derivatives nanoparticles with cells due to their
mucoadhesive character [125-127]. CS nanoparticles have a higher association and internali‐
sation with gastrointestinal tissue cells due to electrostatic interactions compared to polystyr‐
ene nanoparticles [125].More recently, hybrid nanoparticles based on the complexation
between oppositely charged chitosan derivatives (positively charged TMC and negatively
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charged MCC) without using any organic solvent or crosslinker yielded results similar to those
described for the non hybrid nanoparticles [128].
A very promising approach is the development of vaccines based on the initiation of immune
response by transfecting dendritic cells (DC) with DNA encoding tumor-associated antigens
or immunostimulatory molecules such as cytokines or chemokines [129].Although unmodi‐
fied chitosan may not be a good gene delivery carrier for DCs because of its low transfection
efficiency, some modified chitosans showed improved behavior in delivering genes into DCs.
IL-12 gene was delivered to DCs in vivo using mannosylated chitosan (MC) via mannose
receptor-mediated endocytosis [130,131]. MC not only has good physicochemical properties
and low cytotoxicity, but also transfect DCs with much higher efficiency than do the unmodi‐
fied chitosan particles in vitro [130]. In vivo, intratumoral injection of MC /plasmid encoding
murine IL-12 complex into BALB/c mice bearing CT-26 carcinoma cells clearly suppressed
tumor growth and angiogenesis, and significantly induced cell cycle arrest and apoptosis [131].
Mannose-bearing chitosan nanoparticles were also synthesized to entrap complexes of DNA
with polyethyleneimine (PEI) and improve the delivery of DNA into antigen-presenting cells
(APCs) after intramuscular (i.m.) injection [132]. Compared with the traditional chitosan
microspheres, these nanoparticles targeted the DCs (which express a high density of mannose
receptors when they are immature) and released their PEI/DNA cargo inside them. After i.m.
immunization, the MC/PEI/DNA nanospheres induced significantly enhanced serum anti‐
body and cytotoxic T lymphocyte (CTL) responses in comparison to naked DNA [132]. Figure
11 shows the MC/PEI/DNA nanoparticles and superior cumulative DNA release in vitro of
these nanoparticles in PBS buffer as adapted from reference [132].
In recent years, DC vaccines, especially DNA-based DC vaccines, have been the focus of
attention in immunotherapy against cancer [129]. Genetically engineered DCs previously
modified in vitro can then be implanted ex vivo and activate the tumor-specific CTL response
for the killing of cancer cells [129]. Most of these immunotherapy approaches based on DCs
genetic modification for the treatment of melanoma [133,134], renal carcinoma [135] and other
malignant diseases [136] are in phase I/II clinical trials. However, in many of these clinical trials
adenovirus vector is the carrier still employed for DCs modification [137].Since the major
Figure 10. Uptake of chitosan (a), TMC (b) and MCC nanoparticles loaded with bovine serum albumin and labeled
with a green fluorescent marker adapted from reference [124].Reprinted from International Journal of Pharmaceutics,
363/1–2, B. Sayın, S. Somavarapu, X.W. Li, M. Thanou, D. Sesardic, H.O.Alpar, S. Şenel, Mono-N-carboxymethyl chitosan
(MCC) andN-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery, 139-148. Copyright 2008, with
permission from Elsevier.
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barrier for the use of nonviral carriers is their low transfer efficiency compared with viral
vectors, the design of novel and efficient nonviral carriers remains a most warranted area of
research. Recently, CpG was combined with chitosan in order to enhance the Th1 and Th17-
cell polarizing cytokines representing a convenient strategy to elicit cell-mediated immunity
[138].Alum, aluminium phosphate and calcium phosphate adjuvants, as well as biodegradable
PLG microparticles, inhibited the secretion of bioactive IL-12 by DCs.Thus many of the most
widely used adjuvants in preclinical and clinical use exert a specific inhibitory effect on the
secretion of IL-12 by DCs. In contrast, chitosan does not inhibit IL-12 secretion and CpG-
chitosan is a potent stimulus for the induction of pro-inflammatory T-cell responses [138].
CpG-chitosan [138] behaved similarly to DODAB BF/CpG [98].
The design of DC-based vaccines depends strongly on the generation of effective DCs, so that
technologies are needed that produce high antigen expression as a result of delivering DNA
encoding antigen into the nucleus of DCs. Barriers to gene delivery into cells start with cell
adhesion and uptake, escape from endosomes to the cytoplasm prior to fusion with the
lysosomes, trafficking to the nucleus and uptake by the nucleus [139].In particular, large
foreign molecules such as proteins and genes are mostly unable to enter the nucleus of non-
dividing cells. An interesting strategy has been the combination of cationic nanoparticles with
a nuclear localization signal (NLS) which enhanced pDNA delivery to the nucleus of DCs when
combined with electroporation [140].
There is a consensus in the literature that additional immunostimulation provided by LPS,
CpG and other molecules are required to improve the Th1 response of cationic chitosan or
quaternized trimethylchitosan (TMC) [138,141].These nanoparticles containing ovalbumin as
a model antigen (TMC/OVA nanoparticles) and an immunopotentiator (TMC/OVA/immuno‐
potentiator nanoparticles) were recently evaluated [141]. The selection of immunopotentiators
included Tolllike receptor (TLR) ligands lipopolysaccharide (LPS), PAM3CSK4 (PAM), CpG
 
 
icrograph of MC nanoparticles. Release profiles of chitosan
Figure 11. Atomic force micrograph of MC nanoparticles. Release profiles of chitosan and MC nanoparticles as deter‐
mined from 10 mg of nanoparticles suspended in 1 ml of PBS at pH 7.4 (120mM NaCl, 2.7mM KCl, 10mM PBS) at 37 °C
under stirring. At predetermined time intervals, the suspension was centrifuged and replaced with the same volume
of fresh medium. The DNA concentration in the supernatant was determined by absorbance at 260nm.Adapted with
permission from reference [132]. Reprinted from Journal of Controlled Release, 121 /3, Xianfeng Zhou, Bin Liu, Xian‐
ghui Yu, Xizhen Zhang, Yu Chen, Xueyun Wang, Yinghuan Jin, Yongge Wu, Yue Chen, Yaming Shan, Yan Chen, Jun‐
qiu Liu, Wei Kong, Jiacong Shen, Controlled release of PEI/DNA complex from mannose-bearing chitosan
microspheres as a potent delivery system to enhance immune response to HBV DNA vaccine, 200-207. Copyright
2007, with permission from Elsevier.
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DNA, the NOD-like receptor 2 ligand muramyl dipeptide (MDP) and the GM1 ganglioside
receptor ligand, cholera toxin B subunit (CTB). The TMC/OVA/immunopotentiator nanopar‐
ticles were characterised regarding their immunogenicity by determining the serum IgG, IgG1,
IgG2a titres and secretory IgA levels in nasal washes after intradermal and nasal vaccination
in mice. After nasal vaccination, TMC/OVA nanoparticles containing LPS or MDP elicited
higher IgG, IgG1 and sIgA levels than non-adjuvanted TMC/OVA particles, whereas nano‐
particles containing CTB, PAM or CpG did not. After intradermal vaccination, the TMC/OVA/
CpG and TMC/OVA/LPS nanoparticles provoked higher IgG titres than plain TMC/OVA
particles [141]. Co-encapsulation of the antigen and an additional immunopotentiator into
TMC nanoparticles improved the immunogenicity of the vaccine [141].
Nanoparticles of Fe3O4 coated with glutamic acid plus PEI were used to encapsulate DNA
encoding a potent antigen of Mycobacterium tuberculosis (Ag85A-ESAT-6) plus IL-21 generating
a strong immune response and marked growth inhibition of M. tuberculosis in mice [142]. More
importantly, compared with using DNA vaccine Ag85A-ESAT-6-IL-21 alone, the nanoparticle-
based DNA vaccine Ag85A-ESAT-6-IL-21 showed a statistically significant increase in the
protective efficacy against M. tuberculosis infection in the immunized mice [142]. The expres‐
sion of both the fusion protein of Ag85A-ESAT-6 and secreted IL-21 protein was confirmed by
western blot [142]. Cationic poly(lactide-co-glycolide) (PLGA) nanoparticles were obtained by
coating the PLGA nanoparticles with chitosan and used as an intranasal delivery vehicle as a
means of administering foot and mouth disease virus (FMDV) DNA vaccine encoding the
FMDV capsid protein and the bovine IL-6 gene as a means of enhancing mucosal and systemic
immune responses in animals [143]. Guinea pigs and rats were intranasally vaccinated with
the respective chitosan-coated PLGA nano/microparticles-loaded FMDV DNA vaccine
formulations; the IL-6 gene was important as an additional immunoestimulator [143].
Cationized gelatin nanoparticles (GNPs) were used as carriers to improve delivery of immu‐
nostimulatory CpG oligonucleotides (CpG ODN) both in vitro and in vivo [144]. Gelatin
nanoparticles were prepared according to the two step desolvation method including further
optimization [145].Briefly, 1.25 g gelatin was dissolved in 25 ml highly purified water
(5%w/w) at 50oC under constant stirring (700 rpm). The first desolvation step was initiated by
quick addition of 25 ml acetone. After discarding the supernatant containing low molecular
weight fractions of gelatin, the sediment was redissolved in 25 ml water under constant stirring
at 50 oC. Depending on the desired particle size, the pH was then adjusted to a value between
2.3 (approx.resulting particle size: 150 nm) and 3.0 (approx. resulting particle size: 300
nm).Subsequently, the second desolvation step was initiated by drop-wise addition of 50 ml
acetone (during constant stirring at 700 rpm) and resulted in the formation of nanoparticles.
The nanoparticles were stabilized by cross-linking with glutaraldehyde (150 ml of a 25%
solution) under stirring. After 12 h the particles were purified from non-reacted glutaralde‐
hyde by centrifugation and redispersion in water. Cationization of the nanoparticles was
achieved through introduction of a quaternary amino group by covalent coupling of chola‐
minechloride hydrochloride onto the particles surface.The delivery by cationic gelatin
nanoparticles strongly increased the imunostimulatory effects of CpG oligonucleotides [144].
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The effects of CpG are not restricted to modulation of immune responses in vaccine adjuvants.
CpG itself has been considered for the treatment of asthma and other allergic diseases [62].
CpG oligonucleotides (CpG–ODN, resembling bacterial DNA) engage TLR-9 on B-cells,
dendritic cells and other cell types, resulting in a cascade that includes induction of Th1-type
and T-regulatory-type immune responses. Preclinical models of asthma have demonstrated
that CpG–ODN are potent inhibitors of atopic responses, suppressing Th2 cytokine and,
reducing airway eosinophilia, systemic levels of IgE, and bronchial hyperreactivity-in short
the critical attributes of the asthmatic phenotype. In models of chronic allergen exposure, CpG–
ODN are also effective at preventing the development of airway remodeling. In established
asthma, CpG–ODN can reverse manifestations of disease, both when used alone or in
combination with allergen immunotherapy. Early clinical trials have had mixed results,
including a significant benefit when CpG–ODN were conjugated to ragweed allergen in an
allergic rhinitis immunotherapy study, but only limited efficacy seen when administered prior
to allergen challenge in asthmatics [145]. Further study of CpG–ODNs for the treatment of
asthma and other atopic disorders is warranted by existing data.Figure 12 summarizes the
cellular trafficking of CpG [62].
Figure 12. CpG–ODNs are bound by CpG binding protein at the cell surface. The oligonucleotide then undergoes en‐
docytosis where it is bound by TLR9 in the endosome. TLR9 then interacts with MyD88 and the IKK complex and is
translocated to the cell nucleus. Once in the cell nucleus, the CpG ODNs activate NF-kB and initiate the induction of
cytokines and chemokines.Reproduced with permission from reference [62].Reprinted from Advanced Drug Delivery
Reviews, 61 / 3, David E. Fonseca, Joel N. Kline, Use of CpG oligonucleotides in treatment of asthma and allergic dis‐
ease, 256-272. Copyright 2009, with permission from Elsevier.
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Polymer-based nanoscale assemblies based on cationic polymers have been intensively
searched for biomedical applications [146-148]. Poly(2-aminoethyl methacrylate) (PAEM)
cationic homopolymers with defined chain length and narrow molecular weight distribution
were synthesized using atom transfer radical polymerization (ATRP), and PAEM/plasmid
DNA polyplexes interaction with DCs showed its potential for DNA vaccines [149]. PAEM of
different chain lengths (45, 75, and 150 repeating units) showed varying strength in condensing
plasmid DNA into narrowly dispersed nanoparticles with very low cytotoxicity. Longer
polymer chain length resulted in higher levels of overallcellular uptake and nuclear uptake of
plasmid DNA, but shorter polymer chains favored intracellular and intranuclear release of
free plasmid from the polyplexes [149]. When a model antigen-encoding ovalbumin plasmid
was used, transfected DCs stimulated the activation of naïve CD8 (+) T cells to produce high
levels of interferon-γ. The efficiency of transfection, DC maturation, and CD8 (+) T cell
activation showed varying degrees of polymer chain-length dependence [149].These struc‐
turally defined cationic polymers may have much potential as efficient DNA vaccine carriers
and immunoadjuvants.
Other strategies involve the production of hybrid nanoparticles. For example, biocompatible
polymeric particles of poly caprolactone were coated with chitosan for effective immunization
against influenza using recombinant Influenza A virus (A/California/07/2009) H1N1 hemag‐
glutinin (HA) protein, for the induction of humoral, cellular and mucosal immunity [150]. CS-
PCL nanoparticles (cationic nanoparticles) produced humoral (both systemic and mucosal)
and cellular immune responses upon nasal administration demonstrating high potential for
their use as a carrier adjuvant for nasal administered influenza antigens [150]. Other example
is represented by biocompatible core-shell cationic nanoparticles, composed of an inner hard
core of poly(methylmethacrylate) (PMMA) and a hydrophilic tentacular shell bearing posi‐
tively charged groups and poly(ethyleneglycol) chains covalently bound to the core prepared
by emulsion polymerization and characterized in vitro and in vivo for DNA vaccine applica‐
tions [151]. The nanoparticles reversibly adsorbed large amounts of DNA, mainly through
electrostatic interactions, preserved its functional structure, efficiently delivered it intracellu‐
larly, and were not toxic in vitro or in mice [151]. Furthermore, two intramuscular (i.m.)
immunizations (4 weeks apart) with a very low dose (1 microg) of the plasmid pCV-tat
delivered by these nanoparticles followed by one or two protein boosts induced significant
antigen-specific humoral and cellular responses and greatly increased Th1-type T cell re‐
sponses and CTLs against HIV-1 Tat [151].
Chitosan-based DNA vaccines against Japanese encephalitis virus using transdermal immu‐
nization were prepared by using the associative feature of cationic chitosan and anionic DNAs
which formed nanoscale complexes [152]. The expression of green fluorescent protein (GFP)
reporter gene was observable and traceable in epidermis and spleen over 3 days. The expres‐
sions of GFP and the activation of dendritic cells (DCs) were evident and co-localized in hair
follicles and epidermis. Mice immunized with the developed chitosan-JEV DNA vaccines
elicited desired JEV specific antibodies, whereby the mice maintained high survival rates
against 50xLD(50) JEV challenge. The low-pressure-gene-gun mediated chitosan-based JEV
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DNA vaccines have proven to be convenient and efficacious, thereby with high capacity in
deployment for future prophylaxis against JEV outbreaks [152].
Pullulan, a fungal exopolysaccharide produced from starch is a water soluble, neutral linear
biopolymer consisting of α-1,6-linked maltotriose residues. Recently, a cationic cholesteryl
group-bearing pullulan (cCHP) derivative was used to obtain self-assembled nanogels for
administering an intranasal vaccine containing a non-toxic subunit fragment of Clostridium
botulinum type-A neurotoxin BoHc/A (cCHP-BoHc/A) which continuously adhered to the
nasal epithelium and was effectively taken up by mucosal dendritic cells after its release from
the cCHP nanogel. Vigorous botulinum-neurotoxin-A-neutralizing serum IgG and secretory
IgA antibody responses were induced without co-administration of mucosal adjuvant.
Importantly, intranasally administered cCHP-BoHc/A did not accumulate in the olfactory
bulbs or brain. Moreover, intranasally immunized tetanus toxoid with cCHP nanogel induced
strong tetanus-toxoid-specific systemic and mucosal immune responses suggesting that cCHP
nanogel can be used as a universal protein-based antigen-delivery vehicle for adjuvant-free
intranasal vaccination [153].Recently, the same system was used to deliver a vaccine against
pneumonia [154]. This pneumococcal vaccine combined the advantages of pneumococcal
surface protein A (PspA) with a nontoxic intranasal vaccine delivery system based on a
nanometer-sized hydrogel cCHP. The efficacy of the nanogel-based PspA nasal vaccine (cCHP-
PspA) was tested in murine pneumococcal airway infection models. Intranasal vaccination
with cCHP-PspA provided protective immunity against lethal challenge with Streptococcus
pneumoniae Xen10, reduced colonization and invasion by bacteria in the upper and lower
respiratory tracts, and induced systemic and nasal mucosal Th17 responses, high levels of
PspA-specific serum immunoglobulin G (IgG), and nasal and bronchial IgA antibody re‐
sponses. Moreover, there was no sign of PspA delivery by nanogel to either the olfactory bulbs
or the central nervous system after intranasal administration showing the effectiveness and
safety of the nanogel-based PspA nasal vaccine system as a universal mucosal vaccine against
pneumococcal respiratory infection.
Lipid-biopolymer hybrid systems have long been described for incorporation of pDNA
[155].Cationic liposomes mixed with pDNA that had been pre-condensed with a polycation
(e.g.protamine) yielded the LPD formulation or lipid-polymer-DNA (DOTAP, protamine,
pDNA) [156]. As compared to conventional lipoplexes, the double bilayer of LPD confers
greater stability and structural homogeneity to the assemblies [156]. Strong antitumor
immunity could be generated when a peptide antigen was incorporated into LPD (cationic
liposome-polycation-pDNA) nanoparticles [155, 156]. In another study, both the cationic
liposome and DNA were shown to be required for the full immunostimulation activity of LPD
[157]. The unique ability of LPD to readily move into local lymphoid tissues and to activate
antigen-presenting cells might be responsible for its strong immunostimulatory activity [157].
Moreover, cationic liposome stimulates the expression of CD80/CD86 on dendritic cells (DCs),
but not the release of TNF-alpha from DCs, suggesting the existence of a NF-kappa B-
independent immunostimulation pathway for cationic lipids such as DOTAP [157].The LPD
complexes were nanoparticles with less than 100 nm of mean diameter due to the compaction
of DNA induced by the polycation [158].
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Similarly, cationic maltosylated PEI (mPEI) was electrostatically complexed to a plasmid
encoding the human papillomavirus (HPV) type 16L1 protein (pHPV16L1), and further
complexed to a maltose binding protein (MBP)-fused human papilloma virus type 16L1 fusion
protein (HPV16L1-MBP) [159]. The intracellular co-delivery of protein and plasmid DNA
vaccines was significantly higher for mPEI-based triple nanocomplexes than for a simple
physical mixture of the proteins and DNA [160]. The high expression levels were comparable
to those obtained using dual complexes of mPEI and the plasmid DNA. In vivo, co-immuni‐
zation of mice with HPV16L1-MBP/mPEI/pHPV16L1 nanocomplexes triggered the highest
levels of humoral immune responses among various vaccination groups and there was a
significant increase in the number of interferon-γ producing CD8 (+) T cells compared with
the use of mixed proteins and plasmid DNA. This approach could enhance the immunoge‐
nicity of HPV16L1 vaccines [159].
Platelet-derived growth factor-bb (PDGF-BB) and fibroblast growth factor-2(FGF-2) are known
to induce chemotaxis, proliferation, differentiation, and matrix synthesis so that growth factor
therapy is an emerging treatment modality that enhances tissue vascularization, promotes
healing and regeneration and can treat a variety of inflammatory diseases or promote healing
of chronic wounds [160]. Chitosan was combined with PDGF-BB and FGF-2 genes to induce
the therapeutic expression of these genes in mice. The percentage of the residues that are
glucosamine is called the degree of deacetylation (DDA). PDGF-BB and FGF-2 genes were
amplified from human tissues by RT-PCR. To increase the secretion of FGF-2, a recombinant
4sFGF-2 was constructed bearing eight amino-acid residues of the signal peptide of FGF-4.
PCR products were inserted into the expression vector pVax1 to produce recombinant
plasmids pVax1-4sFGF2 and pVax1-PDGF-BB, which were then injected into BALB/C mice in
the format of polyelectrolyte nanocomplexes with specific chitosans of controlled DDA and
molecular weight, including 92-10, 80-10, and 80-80(DDA-number average molecular weight
or M(n) in kDa) [160]. ELISA assays on mice sera showed that recombinant FGF-2 and PDGF-
BB proteins were efficiently expressed and specific antibodies to these proteins could be
identified in sera of injected mice, but with levels that were clearly dependent on the specific
chitosan used [160]. High DDA low molecular weight chitosans were efficient protein
expressors with minimal or no generation of neutralizing antibodies, while lowering DDA
resulted in greater antibody levels and correspondingly lower levels of detected recombinant
protein. Histological analyses corroborated these results by revealing greater inflammatory
infiltrates in lower DDA chitosans, which produced higher antibody titers [160]. The subcu‐
taneous delivery of the plasmids was more efficient than the one by intramuscular injection
[160]. Certain chitosans can be efficient, non-toxic and therapeutic protein delivery systems or
vectors for DNA vaccines [160]. The recent advances that have led to a more rational design
of chitosan polyplexes has recently been reviewed [161]. Recent progress in preparation and
characterisation of chitosan based polyplexes has enabled coupling analysis of chitosans
structural parameters that has led to increased transfection efficiency by tailoring of chitosan's
structure in accordance with a more rational design of chitosan polyplexes [161].
Genetic vaccination against leishmaniasis has been intensively pursued by Rafati´s group
[162-166]. Leishmaniasis is a major health problem in many tropical and sub-tropical countries
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and development of a safe and easily-available vaccine has high priority. Several antigens
potentially capable of inducing protective immunity have been studied like cathepsin L-like
cysteine proteinases (CPs) and type Iand II CPs used in a heterologous prime-boost vaccination
regime for experimental visceral leishmaniasis in dogs. Due to the promising results of the
mentioned vaccination regime, cationic solid lipid nanoparticles (cSLNs) for in vitro delivery
of these antigens were used as a cocktail DNA vaccine to deliver immunogenic CP genes
efficiently. Briefly, the cationic lipid DOTAP (0.4% w/v) was dissolved in hot aqueous phase
which was then added to the melted cetyl palmitate and cholesterol (5.1%w/v) phase contain‐
ing tween 80 as a nonionic surfactant at 3.2:1molar ratio. Emulsification was carried out by
stirring the mixture at 2000 rpm for 10 min at 90oC. Samples were then homogenized using a
high shear homogenizer at 18,000 g for 15 min and the cSLN dispersion was obtained by direct
cooling of hot O/W microemulsion on an ice-bath while stirring at 1000 rpm. The cSLNs were
washed by centrifugation (6000 g, 10 min, three times) using 100 kDa ultra centrifugal filters
to purify the suspension from the excess of surfactant. Efficiency/cytotoxicity ratio of cSLN-
pDNAs formulations was comparable to linear PEI-25KD-pDNAs polyplexes while exhibiting
significantly lower cytotoxicity [162].In addition, C-terminal domain deletion in CPs enhanced
the protective activity of cpa/cpb loaded solid lipid nanoparticles against Leishmania major in
BALB/c mice [163]. cSLN's were able to boost immuneresponse magnitude of cpa/cpb(-CTE)
cocktail vaccination against leishmaniasis so that the average parasite inhibition percent could
be increased significantly [163].The cSLNs were used to formulate three pDNAs encoding L.
major cysteine proteinase type I (cpa), II (cpb) and III (cpc)\[164]. BALB/c mice were immu‐
nized twice with a 3-week interval, with SLN-pcDNA-cpa/b/c, pcDNA-cpa/b/c, SLN, SLN-
pcDNA and PBS.Footpad assessments, parasite burden, cytokine and antibody responses were
evaluated. Mice vaccinated with SLN-pcDNA-cpa/b/c significantly (p<0.05) showed higher
protection levels with specific Th1 immune response development compared to other groups
[164]. This was the first report demonstrating cSLNs as a nanoscale vehicle boosting immune
response quality and quantity [164].
Very fundamental questions regarding size and charge of nanoscale cationic assemblies and
their role in adjuvanticity have seldom been asked and properly answered [167-169]. The role
of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-
induced immune responses was recently evaluated for a series of DOTAP/DOPC cationic
liposomes with different surface densities by incorporating varying amounts of DOPC (a
neutrallipid) into DOTAP (a cationic lipid) [167]. The liposomes with a relatively high charge
density, such as DOTAP/DOPC 5:0 and 4:1 liposomes, potently enhanced dendriticcell
maturation, ROS generation, antigen uptake, as well as the production of OVA-specific IgG2a
and IFN-γ [167]. In contrast, low-charge liposomes, such asDOTAP/DOPC 1:4 liposome, failed
to promote immune responses even at highconcentrations, confirming that the immunoregu‐
latory effect of cationic liposomes is mostly attributable to their surface charge density.
Moreover, the DOTAP/DOPC 1:4 liposome suppressed anti-OVA antibody responses in vivo.
Overall, maintaining an appropriate surface charge is crucial for optimizing the adjuvant effect
of cationic liposomes and enhancing the efficacy of liposome-based vaccines.
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Recently, the high-pressure extrusion method was used to obtain cationic liposomes entrap‐
ping pDNA over a range of sizes [168]. This is a well-known sizing method for liposomes, but
had not been applied for liposomes that are already loaded with pDNA. Liposomes composed
of egg PC, DOTAP, and DOPE with entrapped pDNA were prepared by the dehydration-
rehydration method and subjected to various extrusion cycles, comparing different membrane
pore sizes and extrusion frequencies [168]. At optimized extrusion conditions, liposome
diameter and polydispersity were reduced from 560 nm and 0.56 to 150 nm and 0.14, respec‐
tively, and 35% of the pDNA was retained [168]. Importantly, gel electrophoresis and trans‐
fection experiments with pDNA extracted from these extruded liposomes demonstrated the
preservation of the structural and functional integrity of the pDNA. The reduction in size
resulted in enhanced transfection of HeLa cells, as detected by functional expression of the
fluorescent protein, eGFP. In addition, these liposomes were able to stimulate Toll-like receptor
9, indicating efficient endosomal uptake and release of the included pDNA. In conclusion,
high-pressure extrusion is a suitable technique to size cationic liposomes with entrapped
pDNA and allows preparation of well-defined nanosized pDNA-liposomes, with preserved
pDNA integrity [168]. Their improved transfection efficiency and ability to activate an
important pattern-recognition receptor are favorable properties for DNA vaccine delivery
vehicles [168].
The formulation of DNA into both liposomal and polymeric cationic nanoparticles was found
to block completely vaccination-induced antigen expression in mice and ex vivo human skin
[169].This detrimental effect of cationic nanoparticle formulation was explained by immobili‐
zation of the nanoparticles in the extracellular matrix, caused by electrostatic interactions of
the cationic nanoparticles with negatively charged extracellular matrix components [169].
Shielding the surface charge of the nanoparticles by PEGylation improved in vivo antigen
expression more than 55 fold [169]. Furthermore, this shielding of cationic surface charge
resulted in antigen-specific T cell responses that were similar as those induced by naked DNA
for the two lipo-and polyplex DNA carrier systems tested [169]. Charge shielding should be
generally applied for the development of intradermal vaccine formulations [169].
Various aspects that could be decisive in the formulation of efficient and stable carrier
system(s) for the development of malaria vaccine have recently been reviewed [170]. The
capacity of multi subunit DNA vaccine encoding different stage Plasmodium antigens to induce
CD8+cytotoxic T lymphocytes and interferon-γ responses in mice, monkeys and humans has
been observed [170]. Moreover, genetic vaccination may be capable of eliciting both cell
mediated and humoral immune responses. The cytotoxic T cell responses are categorically
needed against intracellular hepatic stage and humoral response with antibodies targeted
against antigens from all stages of malaria parasite life cycle. Therefore, the key to success for
any DNA based vaccine is to design a vector able to serve as a safe and efficient delivery system.
Also against malaria the development of non-viral DNA-mediated gene transfer techniques
based on artificial vectors such as liposomes, virosomes, microspheres and nanoparticles is
strongly warranted [170].
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4. Conclusions
Cationic nanostructures from lipids, biocompatible polymers, hybrid lipid-polymer or
organic-inorganic systems efficiently combine with important biomolecules such as proteins,
DNA, epitopes and enhancers of the immune response, most of them negatively charged. Their
growing importance for vaccine design becomes evident from the examination of the works
briefly described in this overview.
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